Chargement en cours...

Current clinical evidence on pioglitazone pharmacogenomics

Pioglitazone is the most widely used thiazolidinedione and acts as an insulin-sensitizer through activation of the Peroxisome Proliferator-Activated Receptor-γ (PPARγ). Pioglitazone is approved for use in the management of type 2 diabetes mellitus (T2DM), but its use in other therapeutic areas is in...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kawaguchi-Suzuki, Marina, Frye, Reginald F.
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2013
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3840328/
https://ncbi.nlm.nih.gov/pubmed/24324437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2013.00147
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!